论文信息 - Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications. - 字舞流文

Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

N. Beeching | D. Back | M. Barry | F. Nye | S. Ormesher

[1] R. Macleod,et al. Metabolism of 2',3'-dideoxyinosine (ddI) in human blood. , 1992, British journal of clinical pharmacology.

[2] M. Hirsch,et al. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. , 1990, The Journal of infectious diseases.

[3] S. Broder,et al. Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection , 1990, Clinical pharmacology and therapeutics.

[4] E. Harley,et al. Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism. , 1988, Clinica chimica acta; international journal of clinical chemistry.

[5] C. V. van Ginneken,et al. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. , 1987, British journal of clinical pharmacology.

[6] S. Broder,et al. Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. , 1986, Biochemical pharmacology.

[7] B. Evatt,et al. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. , 1985, The Journal of clinical investigation.